Late Breaking Abstract - Validation of the REVEAL 2.0 Risk Score with the Australian and New Zealand Pulmonary Hypertension Registry Cohort.

J. Anderson (Birtinya, Australia), E. Lau (Sydney, Australia), M. Lavender (Perth, Australia), R. Benza (Pittsburgh, United States of America), D. Celermajer (Sydney, Australia), N. Collins (Newcastle, Australia), C. Corrigan (Sydney, Australia), N. Dwyer (Hobart, Australia), J. Feenstra (Brisbane, Australia), M. Horrigan (Melbourne, Australia), D. Keating (Melbourne, Australia), E. Kotlyar (Sydney, Australia), T. Mcwilliams (Auckland, New Zealand), B. Rhodes (Christchurch, New Zealand), P. Steele (Adelaide, Australia), V. Thakkar (Liverpool, Australia), T. Williams (Melbourne, Australia), H. Whitford (Melbourne, Australia), K. Whyte (Auckland, New Zealand), R. Weintraub (Melbourne, Australia), J. Wrobel (Perth, Australia), A. Keogh (Sydney, Australia), G. Strange (Fremantle, Australia)

Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension
Session: Endpoints and risk assessment of pulmonary arterial hypertension
Session type: Oral Presentation
Number: 495
Disease area: Pulmonary vascular diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Anderson (Birtinya, Australia), E. Lau (Sydney, Australia), M. Lavender (Perth, Australia), R. Benza (Pittsburgh, United States of America), D. Celermajer (Sydney, Australia), N. Collins (Newcastle, Australia), C. Corrigan (Sydney, Australia), N. Dwyer (Hobart, Australia), J. Feenstra (Brisbane, Australia), M. Horrigan (Melbourne, Australia), D. Keating (Melbourne, Australia), E. Kotlyar (Sydney, Australia), T. Mcwilliams (Auckland, New Zealand), B. Rhodes (Christchurch, New Zealand), P. Steele (Adelaide, Australia), V. Thakkar (Liverpool, Australia), T. Williams (Melbourne, Australia), H. Whitford (Melbourne, Australia), K. Whyte (Auckland, New Zealand), R. Weintraub (Melbourne, Australia), J. Wrobel (Perth, Australia), A. Keogh (Sydney, Australia), G. Strange (Fremantle, Australia). Late Breaking Abstract - Validation of the REVEAL 2.0 Risk Score with the Australian and New Zealand Pulmonary Hypertension Registry Cohort.. 495

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Late Breaking Abstract - CPAnet Registry – An International Chronic Pulmonary Aspergillosis Registry
Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond
Year: 2020




Impact of Improved Cookstove Usage on Lung Function in Congolese Refugees: A Prospective Cohort Study.
Source: International Congress 2017 – The air indoor air pollution
Year: 2017



Increased Risk of Heart Failure In Patients of Bronchiectasis – A Nationwide Population-Based Study
Source: International Congress 2019 – Tuberculosis epidemiology, bronchiectasis, other infections and spirometry
Year: 2019

Late Breaking Abstract - Characteristics of Patients Diagnosed with Severe Asthma at UK Specialist Centres: Variation by Ethnicity
Source: International Congress 2019 – Bronchiectasis
Year: 2019

Incidence of Cardiac Complications after Hospitalisation for Community Acquired Pneumonia: A Large Population-based Cohort Study
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020


The Disease Burden of Bronchiectasis in Korea: A National Database Study
Source: International Congress 2019 – Tuberculosis epidemiology, bronchiectasis, other infections and spirometry
Year: 2019


Post-Tuberculosis Bronchiectasis in India:Outcomes of the Indian EMBARC Registry
Source: International Congress 2018 – Pulmonary tuberculosis: long term complications, rehabilitation and challenges
Year: 2018


Late Breaking Abstract - Real-World Characteristics of Patients Receiving Dupilumab in Routine Clinical Practice in a Multinational, Non-Interventional Study (ProVENT)
Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science
Year: 2021


COPD as a Risk Factor in Primary Care: A Canadian Retrospective Cohort Study
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019

Real World Effects of Medications for COPD - a UK Population-Based Non-Interventional Cohort Study With Validation Against Randomised Trial Results
Source: International Congress 2019 – COPD treatment: cohorts and real-world studies
Year: 2019

A Multidisciplinary Multicenter Study Evaluating Risk Factors, Prevalence and Characteristics of Post-COvid-19 Interstitial Lung Syndrome (PCOILS)
Source: Virtual Congress 2021 – Imaging
Year: 2021



Phenotyping Adults with Non-Cystic Fibrosis Bronchiectasis:A 5-Year Cohort Study in a Azerbaijan medical University Center
Source: International Congress 2017 – Clinical challenges in chronic lung diseases
Year: 2017

Association Between Pain Level and Fatigue Level with Activities of Daily Living in Lung Cancer Patients Receiving Inpatient Cancer Therapy: A Pilot Study
Source: Virtual Congress 2020 – A fresh look at the spectrum of symptoms in respiratory disease
Year: 2020


Late Breaking Abstract - NORdic Database for aSThmA Research (NORDSTAR): Swedish and Finnish patients
Source: International Congress 2018 – Epidemiology of asthma and allergy: prevalence, incidence and risk factors
Year: 2018


Risk Score for Subclinical COPD: The NHLBI Pooled Cohorts Study
Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases
Year: 2020




ISHLT Registry Data and Country Registries: Comparison of reported European Lung Transplant Activities in 2016
Source: International Congress 2019 – Lung transplantation: from basic science to clinical outcomes
Year: 2019


Late Breaking Abstract - Standard-of-Care Asthma Controller Regimen Reduction with Benralizumab Treatment: ANDHI In Practice Study
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021


Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration
Source: Eur Respir J, 55 (5) 2001047; 10.1183/13993003.01047-2020
Year: 2020



Influence of Smoking, Environmental  Factors and Life Style on Lung Function in a Large German Cohort
Source: International Congress 2018 – Occupational and environmental lung diseases: inhaled air quality and health effects
Year: 2018

Evaluation of COPD Patient’s Relatives Assessment of Disease Awarness, Load of Care Giving and Loss of Workforce: Turkish Thoracic Society COPD Working Group.
Source: International Congress 2018 – Patient-reported outcomes and scores in COPD
Year: 2018